journal
https://read.qxmd.com/read/37782426/immune-related-adverse-events-in-patients-with-lung-cancer
#1
REVIEW
Guilherme Sacchi de Camargo Correia, Tanmayi Pai, Shenduo Li, Dana Connor, Yujie Zhao, Yanyan Lou, Rami Manochakian
PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICI) have been widely adopted for the treatment of lung cancer since receiving first U.S Food and Drug Administration (FDA) approval in 2015. However, along with their use, the occurrence of immune-related adverse events (irAEs) has presented a challenge for both patients and oncology providers. In this manuscript, we reviewed the clinical trials that led to the approval of ICI by the FDA for the treatment of lung cancer between 2015 and 2023 to establish the frequency of irAEs in this patient population...
October 2, 2023: Current Oncology Reports
https://read.qxmd.com/read/37773078/mucosal-melanoma-epidemiology-clinical-features-and-treatment
#2
REVIEW
Maria Chiara Sergi, Elisabetta Filoni, Giacomo Triggiano, Gerardo Cazzato, Valeria Internò, Camillo Porta, Marco Tucci
PURPOSE OF REVIEW: Summarize the writings published in the last years on the management and novel therapies of mucosal melanoma (MM). RECENT FINDINGS: New research has demonstrated a difference between MM and cutaneous melanoma (CM) in their genomic and molecular landscapes, explaining the response's heterogeneity. Immunotherapy and targeted therapy have limited benefit, but novel therapies are rapidly expanding. MM is aggressive cancer occurring in gastrointestinal, respiratory, or urogenital mucosa; whose incidence is greater in the Asian population...
September 29, 2023: Current Oncology Reports
https://read.qxmd.com/read/37768467/correction-enhanced-recovery-in-gynecologic-oncology-surgery-state-of-the-science
#3
Gregg Nelson
No abstract text is available yet for this article.
September 28, 2023: Current Oncology Reports
https://read.qxmd.com/read/37715884/exercise-as-medicine-in-cardio-oncology-reducing-health-disparities-in-hispanic-and-latina-breast-cancer-survivors
#4
REVIEW
Paola Gonzalo-Encabo, Nathalie Sami, Rebekah L Wilson, Dong-Woo Kang, Salvatore Ficarra, Christina M Dieli-Conwright
PURPOSE OF REVIEW: This review aims to access the current state of the evidence in exercise as medicine for cardio-oncology in Hispanic and Latina breast cancer survivors and to provide our preliminary data on the effects of supervised aerobic and resistance training on cardiovascular disease (CVD) risk in this population. RECENT FINDINGS: Breast cancer survivors have a higher risk of CVD; particularly Hispanic and Latina breast cancer survivors have a higher burden than their White counterparts...
September 16, 2023: Current Oncology Reports
https://read.qxmd.com/read/37702983/chemotherapy-induced-peripheral-neuropathy-diagnosis-agents-general-clinical-presentation-and-treatments
#5
REVIEW
Diana Molinares, Sara Kurtevski, Yingrong Zhu
PURPOSE OF REVIEW: This review aims to discuss pathophysiology, diagnosis, clinical presentation, and treatment of chemotherapy-induced peripheral neuropathy. Agent-specific presentation and pathophysiology is also being discussed. RECENT FINDINGS: As new systemic oncological treatments continue to be developed, the number of cancer survivors continues to grow. Survivors are living longer with the long-term side effects of oncological treatments. We reviewed the pathophysiology of agent-specific chemotherapy-induced peripheral neuropathy and the updates in its treatment and preventative tools...
September 13, 2023: Current Oncology Reports
https://read.qxmd.com/read/37695399/correction-to-extramammary-paget-disease-a-therapeutic-challenge-for-a-rare-entity
#6
Jesús Chamorro Pérez, Alfonso Cortes Salgado, Belén Perez-Mies, Jose Antonio Domínguez Rullán, Odile Ajuria-Illarramendi, Eva María Guerra Alia, Juan José Serrano Domingo
No abstract text is available yet for this article.
September 11, 2023: Current Oncology Reports
https://read.qxmd.com/read/37695398/new-developments-in-image-guided-percutaneous-irreversible-electroporation-of-solid-tumors
#7
REVIEW
Jung H Yun, Adam Fang, Fereshteh Khorshidi, Peiman Habibollahi, Oleksandra Kutsenko, Vahid Etezadi, Stephen Hunt, Nariman Nezami
PURPOSE OF REVIEW: This review will describe the various applications, benefits, risks, and approaches of conventional irreversible electroporation (IRE), as well as highlight the new technological developments of this procedure along with their clinical applications. RECENT FINDINGS: Minimally invasive image-guided percutaneous IRE ablation has emerged as a newer, non-thermal ablation technique for tumors in the solid organs, particularly within the liver, pancreas, kidney, and prostate...
September 11, 2023: Current Oncology Reports
https://read.qxmd.com/read/37688739/adjuvant-and-neoadjuvant-treatments-for-resectable-hepatocellular-carcinoma
#8
REVIEW
Christiana J Crook, Daneng Li
PURPOSE OF REVIEW: This review provides an update on the developments of adjuvant and neoadjuvant liver-directed and systemic therapy options for patients with resectable hepatocellular carcinoma. RECENT FINDINGS: Data on liver-directed treatment in the adjuvant and neoadjuvant settings are sparse and results are conflicting; many studies suggest that optimizing patient selection criteria is a key milestone required to improve study design and clinical benefit to patients...
September 9, 2023: Current Oncology Reports
https://read.qxmd.com/read/37688738/approach-to-the-older-patient-with-acute-myeloid-leukemia
#9
REVIEW
Markie Zimmer, Tapan Kadia
PURPOSE OF REVIEW: This study aims to review the challenges of treating AML in older patients, the spectrum of genomic aberrancies in this cohort, and discuss treatment options for newly diagnosed AML in this patient population. RECENT FINDINGS: Greater understanding of biological underpinnings of AML and availability of newer, effective, targeted therapies have allowed us to move away from intensification of chemotherapy, to prioritize better tolerability while still maintaining efficacy...
September 9, 2023: Current Oncology Reports
https://read.qxmd.com/read/37682487/next-generation-sequencing-optimal-sequencing-of-therapies-in-relapsed-refractory-chronic-lymphocytic-leukemia-cll
#10
REVIEW
Florian Simon, Jan-Paul Bohn
PURPOSE OF REVIEW: This research paper aims to provide an overview of evidence-based sequencing of therapies in relapsed/refractory chronic lymphocytic leukemia (CLL) in the era of targeted drugs. RECENT FINDINGS: In the absence of data from randomized clinical trials comparing novel agents head-to-head, growing evidence suggests that patients with late relapse (> 2 years) after fixed-duration therapies benefit from identical retreatment, whereas a class switch is favorable in those with short-lived remissions or progressive disease on continuous drug intake...
September 8, 2023: Current Oncology Reports
https://read.qxmd.com/read/37646901/interventional-treatment-options-for-post-mastectomy-pain
#11
REVIEW
Aarthi Murugappan, Ashish Khanna
PURPOSE OF REVIEW: Breast cancer is currently the most prevalent cancer diagnosed globally, and there is a significant gap in the availability of effective first-line treatment options. In addition to a cancer diagnosis, breast cancer patients face additional pain and morbidity after treatment. Radiation fibrosis, muscle spasms, muscle pain, neuropathy, and limited shoulder function are all potential side effects of breast cancer treatment and breast reconstruction. Post-mastectomy pain syndrome affects 25-60% of people after breast surgery...
August 30, 2023: Current Oncology Reports
https://read.qxmd.com/read/37646900/cellular-therapy-in-nsclc-between-myth-and-reality
#12
REVIEW
Martina Imbimbo, Laureline Wetterwald, Alex Friedlaender, Kaushal Parikh, Alfredo Addeo
PURPOSE OF REVIEW: In this paper, we review the current state and modalities of adoptive cell therapies (ACT) in non-small cell lung carcinoma (NSCLC). We also discuss the challenges hampering the use of ACT and the approaches to overcome these barriers. RECENT FINDINGS: Several trials are ongoing investigating the three main modalities of T cell-based ACT: tumor-infiltrating lymphocytes (TILs), genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T cells...
August 30, 2023: Current Oncology Reports
https://read.qxmd.com/read/37624551/integration-of-postoperative-radiation-therapy-with-cyclin-dependent-kinase-cdk-inhibitors
#13
REVIEW
Fernanda Hayashida Yoshimoto, Cecilia Félix Penido Mendes de Sousa, Gustavo Nader Marta, Samir Abdallah Hanna
PURPOSE OF REVIEW: Sequential use of radiation therapy before cyclin-dependent kinase (CDK) inhibitors in women with early breast cancer seems reasonable and with a low toxicity rate. This study aimed to evaluate the possible interaction between RT and CDK inhibitors in the adjuvant setting for patients with positive hormone receptors and HER-2 negative, investigating toxicity and the treatment sequencing. RECENT FINDINGS: CDK inhibitors have been studied in patients with localized breast cancer and can improve invasive disease-free survival outcomes...
August 25, 2023: Current Oncology Reports
https://read.qxmd.com/read/37624550/role-of-body-composition-in-the-prediction-of-skeletal-fragility-induced-by-hormone-deprivation-therapies-in-cancer-patients
#14
REVIEW
Alberto Dalla Volta, Irene Caramella, Pierluigi Di Mauro, Marco Bergamini, Deborah Cosentini, Francesca Valcamonico, Carlo Cappelli, Marta Laganà, Nunzia Di Meo, Davide Farina, Rebecca Pedersini, Gherardo Mazziotti, Alfredo Berruti
PURPOSE OF REVIEW: This review paper is intended to show that changes in body composition are key in the pathogenesis of bone fragility amongst patients with breast and prostate cancer receiving hormone deprivation therapies (HDTs) and that the mechanism is based on the development of alterations in bone quality rather than in bone quantity. RECENT FINDINGS: Preclinical and clinical data suggest a tight connection amongst bone, adipose and muscular tissues by means of several soluble mediators, potentially leading to (1) bone resorption and bone quality deterioration in sarcopenic obese subjects, (2) bone mineral deposition in healthy trained subjects...
August 25, 2023: Current Oncology Reports
https://read.qxmd.com/read/37606874/managing-metastatic-extrapulmonary-neuroendocrine-carcinoma-after-first-line-treatment
#15
REVIEW
Nikolaos Andreatos, Patrick W McGarrah, Mohamad Bassam Sonbol, Jason S Starr, Jaume Capdevila, Halfdan Sorbye, Thorvardur R Halfdanarson
PURPOSE OF REVIEW: Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare, aggressive malignancy that can arise from any organ and frequently presents with distant metastases. Advanced disease has a poor prognosis with median overall survival (OS) rarely exceeding 1 year even with systemic therapy. The management paradigm of advanced/metastatic EP-NEC has been extrapolated from small cell lung cancer (SCLC) and commonly consists of 1st line therapy with etoposide and platinum (cisplatin or carboplatin), followed by alternative cytotoxic regimens at the time of progression...
August 22, 2023: Current Oncology Reports
https://read.qxmd.com/read/37603119/dedifferentiated-chondrosarcoma-diagnostic-controversies-and-emerging-therapeutic-targets
#16
REVIEW
Marc El Beaino, Syed T Hoda, Ahmed J Eldeib, Karim Masrouha
PURPOSE OF REVIEW: The pathogenesis of dedifferentiated chondrosarcoma is controversial, and no genetic abnormality has consistently been identified in the disease. Focusing on the diagnostic challenges encountered in dedifferentiated chondrosarcoma, the following review aims at summarizing the tumor's active neoplastic pathways while highlighting therapeutic modalities that could potentially be explored to enhance patient survivorship. RECENT FINDINGS: Owing to the challenging examination of small needle biopsy sampling as well as the disease's overlapping morphological and immunohistochemical features with other bone and soft-tissue sarcomas, the diagnosis of dedifferentiated chondrosarcoma can be problematic...
August 21, 2023: Current Oncology Reports
https://read.qxmd.com/read/37589940/cardiac-arrhythmias-in-oncological-patients-epidemiology-risk-factors-and-management-within-the-context-of-the-new-esc-2022-guidelines
#17
REVIEW
Michał Gawlik, Jakub Michal Zimodro, Aleksandra Gąsecka, Krzysztof J Filipiak, Sebastian Szmit
PURPOSE OF REVIEW: To provide an update on epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients within the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology. RECENT FINDINGS: One of the side effects of different chemotherapeutics is their pro-arrhythmic activity. Both atrial and ventricular arrhythmias may be induced by cancer itself or by anticancer treatment. Recent studies report on the cardiotoxic activity of such promising therapies as BRAF and MEK inhibitors, or CAR-T therapy...
August 17, 2023: Current Oncology Reports
https://read.qxmd.com/read/37490193/enhanced-recovery-in-gynecologic-oncology-surgery-state-of-the-science
#18
REVIEW
Gregg Nelson
PURPOSEOF REVIEW: The purpose of this review is to describe the state of the science of enhanced recovery after surgery (ERAS) in gynecologic oncology. RECENT FINDINGS: Over the last 5 years, there is mounting evidence supporting ERAS in gynecologic oncology surgery. Despite this, surveys have found suboptimal uptake of ERAS, and stakeholders have highlighted the difficulty of ERAS implementation as a major barrier. To address this, the core components required for a successful ERAS implementation program (protocol, ERAS team, audit system) are reviewed...
July 25, 2023: Current Oncology Reports
https://read.qxmd.com/read/37470973/disease-assessments-in-patients-with-glioblastoma
#19
REVIEW
Kester A Phillips, David O Kamson, David Schiff
PURPOSE OF REVIEW: The neuro-oncology team faces a unique challenge when assessing treatment response in patients diagnosed with glioblastoma. Magnetic resonance imaging (MRI) remains the standard imaging modality for measuring therapeutic response in both clinical practice and clinical trials. However, even for the neuroradiologist, MRI interpretations are not straightforward because of tumor heterogeneity, as evidenced by varying degrees of enhancement, infiltrating tumor patterns, cellular densities, and vasogenic edema...
July 20, 2023: Current Oncology Reports
https://read.qxmd.com/read/37466849/kidney-cancer-integrative-oncology-possible-options-for-care
#20
REVIEW
Samuel Mathis, Victor S Sierpina
PURPOSE OF REVIEW: This study aims to review how complementary and integrative medicine (CIM), defined as therapies utilizing nutrition, physical activity, herbs, supplements, mind-body therapies, homeopathy, and other non-traditional therapies, can address the prevention, treatment, side effects, and recurrence of kidney cancer. This review discusses advances and discoveries in research, gaps in research, current debates on the subject, and directions for future research. We queried Ovid MEDLINE and PubMed databases using the search terms kidney cancer, integrative medicine, integrative oncology, nutrition, supplements, treatment, prevention, and therapy...
July 19, 2023: Current Oncology Reports
journal
journal
34702
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.